Alkermes saw a welcome improvement to its Relative Strength (RS) Rating on Friday, rising from 69 to 74.
This proprietary rating tracks technical performance by showing how a stock's price movement over the last 52 weeks compares to that of the other stocks in our database.
Over 100 years of market history reveals that the market's biggest winners tend to have an RS Rating north of 80 as they begin their biggest runs. See if Alkermes can continue to rebound and clear that threshold.
How To Invest In Stocks In Both Bull And Bear Markets
Alkermes is not currently showing a potential buy point. See if the stock goes on to build a base that could spark a new run.
Earnings growth declined in the most recent quarter from -8% to -16%. But sales moved higher, from -35% to -1%.
The company holds the No. 28 rank among its peers in the Medical-Biomed/Biotech industry group. Catalyst Pharmaceuticals, Halozyme Therapeutics and ADMA Biologics are among the top 5 highly rated stocks within the group.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Which Stocks Are Showing Rising Relative Strength?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!